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RMCE-based Sf9 cell factory for 
production of multi-meric VLPs
Ana Teixeira
Vaccine Technology IV, May 23 2012
Multi-Protein Complexes
Multi-Protein complexes:
• Their study is essential for drug design                     
(e.g. membrane receptors, intracellular kinase complexes) 
• involved in numerous biological functions 
• connected with the development of severe diseases 
• Used as biopharmaceuticals (mAbs, VLPs)
In most cases recombinant 
production required! 
3D structure required to 
understand cellular processes 
Bottleneck:
Lack of efficient 
production tools
Aim: high quality and 
quantity for
i) pharmaceutical manufacturing
ii) Drug discovery research
Influenza virus Influenza VLP
Courtesy D. Jordan
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Infected cells
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Preferred Eukaryotic system for production of Multi-protein complexes
VP7
VP6
Single-infection with multicistronic rBacCo-infection with monocistronic rBac
1) Strong promoters (polh and p10) - good protein expression levels;
2) Similar protein folding and PTMs to mammalian cells; 
3) The baculovirus genome allows expression of large transgenes and multiple genes.
Key advantages
Virus Recombinant Proteins Size (nm) Product Status
Adeno-associated virus VP1, VP2, VP3 20-25 Development
Bluetongue virus VP2, VP3, VP5, VP7 69 Preclinical
Ebola virus VP40 and glycoprotein 65-70 Preclinical
Enterovirus 71 VP0, VP1, VP2 25-27 Preclinical
H1N1 Influenza virus HA, NA, M1 80-120 Phase IIa (Novavax)
H3N2 Influenza virus HA, NA, M1 80-120 Phase IIa (Novavax)
H5N1 Influenza virus HA, NA, M1 80-120 Phase I/IIa (Novavax)
Baculovirus expression vector system (BEVS) has been 




















Hepatitis C virus Core, E1 and E2 proteins 40-60 Preclinical
Human immunod virus Pr55gag and env proteins 100-120 Preclinical
Human papiloma virus L1 capsid protein 30-50 Cervarix (GSK)
Infectious bursal disease virus VP2, VP3, VP4 60-65 Development
Marburg virus VP40 and glycoprotein 50-100 Preclinical
Norwalk virus Capsid protein 38 Phase I (LigoCyte Pharma)
Poliovirus VP0, VP1, VP3 27 Development
Porcine parvovirus VP2 22 Preclinical
Rotavirus VP2, VP6, VP7 70-80 Preclinical
Simian immunod virus Pr56gag and env proteins 130 Preclinical
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vp6 trimers &  vp7 trimers
100nm
Alternative to the Baculovirus-insect cell system
Sf9 cell platform
Advantages: 
 Growth to high cell densities
 Serum-free culture medium
 Eukariotic post-translational modifications
 Very efficient metabolism
 No lactate or ammonia accumulation
BEVS
Drawbacks: 
 Effort to maintain the virus stock
 Lytic infection, proteases
 Hard to separate viral and rec proteins
 Very late promoters – protein processing 
machinery compromised



































































































Recombinase-Mediated Cassette Exchange (RMCE) System
RMCE involves 2 steps:
1) To tag and select for a high expression locus
2) To target the locus of interest
Flipase Recombination
5’- GAAGTTCCTATTC – TCTAGAAA – GTATAGGAACTT-3’
3’- CTTCAAGGATAAG– AGATCTTT – CATATCCTTGAAG -5’
Flp recognition target (FRT):
spacer13 bp repeat 13 bp repeat
Binding sites Binding sites
Homology required
Exploitation of a defined locus by RMCE



















compared in terms 
of GFP expression Higher expression from OpIE2 
Tagging and targeting cassette design
Recombination 
triggers activation of 












OpIE1 has lower expression, but suitable for antibiotic resistance expression Fernandes et al. Biotechnol Bioeng in press
Tagging cassette
STEP 1 – Tagging = identification stable 
high expression locus
•Selection w/ Hyg
•Screening w/ reporter gene










with different DNA amounts
Aim: clones with single-
copy integration
STEP 2 – Targetting = reuse the same 
locus bt RMCE
•Selection w/ neomycin
•Predicatble expression of the 
gene of interest (GOI)
4 cell populations selected during 3 weeks
Electroporation 




250V, 1 µg DNA
Cellfectin
0.3 µg DNA
- Substantially different populations 
in terms of fluorescence distribution
Establishing a Flexible Sf9 cell line: Clone screening








































- Identification of clones with single-copy integration
• Single copy integration: only one band of
variable size, as restriction enzymes (EcoRI/SacI)
cut only once inside the tagging cassette
All analyzed clones have single copy 




















STEP 1 – Tagging = identification stable 
high expression locus
•Selection w/ Hyg
•Screening w/ reporter gene








Establishing a Flexible Sf9 cell line: Cassette exchange
STEP 2 – Targetting = reuse the same 
locus bt RMCE
•Selection w/ neomycin
•Predicatble expression of the 
gene of interest (GOI)
Δneo 
Fw F5





Establishing a Flexible Sf9 cell line: Cassette exchange
- Tagging clones were co-transfected with 
flipase plasmid and target cassette
72 h post-transfection
Clone #2
After 3 weeks in G418 Selection
- G418 resistance
- decrease in dsRed cells
- increase in GFP cells
Suggestion of 
correct RMCE
Fernandes et al. Biotechnol Bioeng in press
Lanes 1 , 3, 5 – Expression before cassette exchange
Lanes 2, 4, 6 – Upon cassette exchange and 3 weeks in 
selection
mRNA levels of dsRed 
decreased and GFP increased
Establishing a Flexible Sf9 cell line: Cassette exchange
dsRed EGFP 18S
Clone #2 
PCR of genomic DNA confirms cassette exchange
+flipase
First proof of flp-mediated 
recombination in Sf-9 cells
1600 bp
600 bp
The difference in 1000 bp confirms 
lack of hygromycin gene
- The same primers were used:






Fernandes et al. Biotechnol Bioeng in press
Establishing a Flexible Sf9 cell line: Target Clones
Expression predictability
- Stronger dsRed producer clones resulted in 
stronger eGFP producer clones
























- Colonies derived from the same master cell 
clone showed similar expression patterns. 
predictability in Sf9 cells










No need for extensive screening upon 
transfection with the gene-of-interest




















RMCE-based stable expression vs BEVS
96h 192h
#3 #3 #3










Clone 2 41.9 ± 4.2 6.2 ± 0.6 0.079 ± 0.004 47.9 ± 4.07
Clone 3 41.7 ± 5.8 4.8 ± 0.5 0.078 ± 0.004 44.2 ± 3.69
Baculovirus infection
MOI=0.1, CCI=3
a 3.9 ± 0.4 0.140 ± 0.008 67.9 ± 5.67
- Similar eGFP titers to those obtained with BEVS; 
- More room for improvement
Fernandes et al. Biotechnol Bioeng in press
















OpIE2OpI 2 OpIE1 Mena et al. J Biotech 2006, 122:443–452
200nm






Validation with target proteins







Two Cassette Exchange Systems: Increasing Flexibility 
Strategy:
1) Anchor 2 reporter cassettes, each flanked by a distint 
• New mutant FRT site variants, incompatible /non-
cross interacting with those of the first cassette
Aim: cell line for multi-meric
biopharmaceutical production
pair of FRTs (Fw-F5; F13-F14) in Sf9 cell genome;
2) Select and screen for clones expressing high levels of 
both reporter genes, each from single-copy integration;
• Hygromycin
• G418
• FACS (red and 
green cells)
3) Simultaneous Flp-mediated cassette exchange at both 
genomic sites
Two Cassette Exchange Systems: Increasing Flexibility 









Exchange of 2 reporter cassettes (anchored in “hot 










Only cells that exchange both 
cassettes survive to selection
Master Sf9 cell line: Expression of HCMV gB Protein
gB - transmembrane glycoprotein, required 
for virion-mediated membrane fusion
Cytomegalovirus
Marco Patrone
Structure of the gB ectodomain is available 
(trimeric post-activation arrangement)
Heldwein et al. 2006. Science 313:217-20
An anti-HCMV vaccination strategy 











• The membrane portion of gB is required for its synthesis in pre-activation, fusion competent state 
• Full-length gB can be used to screen for fusion inhibitors in virus-free settings
Master Sf9 cell line: Expression of HCMV gB Protein
Cytomegalovirus
Marco Patrone
Production Platform: BEVS / HighFive cells 
- After process optimisation, 25 L bioreactor 
culture yielded 9 mg of purified gB protein 






• 9,600 trials/day with 0.48 mL
• Microfluidics for direct orthogonal screen&optimize
• In situ X-ray diffraction for crystal quality assessment
Antigenic analysis 
in vitro and in vivo
Can FL-gB suggest a better 
HCMV vaccine design?





 First application of Flp/FRT recombination in insect cell lines:
 Single-copy integration achieved
 Neo-based trap system allowed selection of correctly targeted cells 
 Demonstration of RMCE advantages in Sf9 cells:
 Clones derived from the same master cell line showed similar expression
 Consistent expression of dsRed and EGFP for corresponding tagged and 
target clones 
No need for extensive clone screening 
after transfection with GOI
Summary
 EGFP expression titer similar to that achieved using the BEVS:
 but wider room for improvement through medium/process engineering
 Site specific integration of VP2 and gB
 Promissing production levels of difficult to express proteins
 Use of incompatible pairs of FRT sites to anchor 2 cassettes in the same cell 
 double cassette exchange in a single step
Re-usable cell platform to produce multiple rec proteins:
 skipping extensive clone screening 
 alternative to baculovirus infection
 single or multiple protein expression 
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